Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

NCT ID: NCT06481228

Last Updated: 2025-08-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-04
• Study Completion Date: 2028-06-01

Brief Summary

In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL. The available data suggest that the advancement of immunotherapy from R/R field to the frontline setting may be an important approach to increase the depth of remission, which ultimately translates into a survival benefit. In this study, the investigators propose a treatment regimen using CAR-T cell therapy as a consolidation method for Ph+ ALL patients achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy, aiming to reduce the total cycles of chemotherapy and related toxicities, shorten length of hospitalization, and ultimately improve patients' survival and quality of life.

Detailed Description

The CAR-T cells were murine-derived second-generation CD19 CAR-T with a co-stimulation domain of 4-1BB, and the infusion dose was 1×10^6/kg CAR+ cells in a single infusion.

Conditions

Philadelphia Positive Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, Adult

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TKI Combined With Chemotherapy and Sequential CAR-T Cells

Ph+ALL patients receiving CAR-T cells as consolidation therapy after achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy.

Group Type: EXPERIMENTAL

CAR-T cells

Intervention Type: COMBINATION_PRODUCT

CAR-T cells as consolidation therapy

Venetoclax

Intervention Type: DRUG

BCL2 inhibitor

Olverembatinib

Intervention Type: DRUG

TKI

Interventions

CAR-T cells

CAR-T cells as consolidation therapy

Intervention Type: COMBINATION_PRODUCT

Venetoclax

BCL2 inhibitor

Intervention Type: DRUG

Olverembatinib

TKI

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged 18 years or older

2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic leukemia

3. CD19 expression on blasts

4. Expected survival time greater than 3 months

5. Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal（ULN）; serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ejection fraction ≥ 45%

6. Subject has provided written informed consent prior to any screening procedure

Exclusion Criteria

1. Lymphoid blast crisis of chronic myelocytic leukemia (CML)

2. Previous or ongoing systemic anti-ALL therapy (including but not restricted to TKI and/or radiotherapy, except for appropriate pre-treatment)

3. Patients with a history of myocardial infarction within 12 months or clinically significant cardiac disorders disease (e.g., unstable angina, congestive heart failure, uncontrollable hypertension, uncontrollable arrhythmia, etc.)

4. Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment

5. Known HIV seropositivity

6. History of acute pancreatitis within 1 year of study screening or history of chronic pancreatitis

7. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)

8. Another malignancy diagnosed and treated within 5 years prior to diagnosis or previously diagnosed with another malignancy with evidence of residual disease. Patients with non-melanoma skin cancer or any type of carcinoma in situ that has been completely excised should not be excluded

9. Female patients who are pregnant or breast feeding

10. Clinical manifestations of active CNS or extramedullary involvement with ALL

11. Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded

12. Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment

13. Other conditions assessed by the investigators to be inappropriate for this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jianxiang Wang, Dr

Role: PRINCIPAL_INVESTIGATOR

Institute of Hematology & Blood Diseases Hospital, China

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jianxiang Wang, Dr

Role: CONTACT

wangjx@ihcams.ac.cn

86-22-23608451

Facility Contacts

Jianxiang Wang, Dr.

Role: primary

wangjx@medmail.com.cn

86-22-23909120

Other Identifiers

IIT2024019

Identifier Type: -

Identifier Source: org_study_id